FiercePharma

Seeking to shake up eye inflammation market, Optifye and DelSiTech partner on controlled-release drops

Optifye Therapeutics has struck a deal with DelSiTech for controlled-release dexamethasone eye drops. The exclusive license agreement covers a candidate that uses DelSiTech Silica Matrix technology to ...
Healio

Using intracanalicular dexamethasone insert after cataract surgery saves office time

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Using Dextenza as a postoperative steroid treatment after cataract surgery saved practices about ...
Healio

OCS-01 eye drop for DME in second stage of phase 3 trial

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PARK CITY, Utah — Stage one of the phase 3 DIAMOND trial ...
Nasdaq

Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for ...

DEXTENZA was observed to have a favorable safety profile and be generally well-tolerated in the allergic conjunctivitis as well as the ocular inflammation and pain clinical populations. The most ...
Business Wire

Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching ...

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for ...